Kliininen tutkimuskeskus
Clinical Research Center

Julkaisut 2003
Publications 2003

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Arikoski P et al. Bone mineral density in long-term survivors of childhood cancer.
2 Cheng S et al. Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls.
3 Chiasson J-L et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOPP-NIDDM Trial.
4 Eriksson J et al. The effects of the Pro12Ala polymorphism of the PPARgamma-2 gene on lipid metabolism interact with body size at birth.
5 Eriksson JG et al. Interactions between peroxisome proliferator-activated receptor gene polymorphism and birth length influence risk for type 2 diabetes.
6 González-Sánchez JL et al. K121Q PC-1 gene polymorphism is not associated with insulin resistance in a Spanish population.
7 Haara MM et al. Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality.
8 Hakulinen MA et al. Dual energy x-ray laser measurement of calcaneal bone mineral density.
9 Hiltunen MO et al. Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo.
10 Huopio H et al. A new subtype of autosomal dominant diabetes attributabe to a mutation in the gene for sulfonylurea receptor 1.
11 Kettunen J et al. Bone mineral density after removal of rigid plates from forearm fractures: preliminary report.
12 Kolehmainen M et al. Effect of the pro12ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects.
13 Komulainen M et al. Luut murtuvat ilman estrogeenia.
14 Korhonen S et al. Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome.
15 Kossila M et al. Promoter polymorphisms -359T/C and -303A/G of the catalytic subunit p110beta gene of human phosphatidylinositol 3-kinase are not associated with insulin secretion or insulin sensitivity in Finnish subjects.
16 Kröger H et al. Osteoporosis and the orthopaedic surgeon.
17 Kubaszek A et al. The K121Q polymorphism of the PC-1 gene is associated with insulin resistance but not with dyslipidemia.
18 Kubaszek A et al. Promoter polymorphisms of the TNF-alfa (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study.
19 Kubaszek A et al. The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity .
20 Kärkkäinen S et al. A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy.
21 Lindi V et al. Impact of the pro12ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n - 3 fatty acid supplementation. For the KANWU study group.
22 Niskanen L et al. Association of the PRO12ALA polymorphism of the PPAR-gamma2 gene with oxidized low-density lipoprotein and cardiolipin autoantibodies in nondiabetic and type 2 diabetic subjects.
23 Pajukanta P et al. Combined analysis of genome scans of Dutch and Finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q.
24 Reimann F et al. Characterisation of new KATP-channel mutations associated with congenital hyperinsulinism in the Finnish population.
25 Remes T et al. Aerobic exercise and bone mineral density in middle-aged Finnish men: a controlled randomized trial with reference to androgen receptor, aromatase, and estrogen receptor alfa gene polymorphisms.
26 Salmén T et al. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
27 Salmén T et al. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.
28 Sipola P et al. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the asp 175asn mutation of the alfa-tropomyosin gene.
29 Sipola P et al. Cardiac adrenergic activity is associated with left ventricular hypertrophy in genetically homogenous subjects with hypertrophic cardiomyopathy.
30 Sirola J et al. Factors affecting bone loss around menopause in women with HRT: a prospective study.
31 Sirola J et al. Risk factors associated with peri- and postmenopausal bone loss: does HRT prevent weight loss-related bone loss?
32 Sirola J et al. Smoking may impair the bone protective effects of nutritional calcium: a population-based approach.
33 Sirola J et al. Interaction of nutritional calcium and HRT in prevention of postmenopausal bone loss: a prospective study.
34 Sivenius K et al. A deletion in the alfa2B-adrenergic receptor gene and autonomic nervous function in central obesity.
35 Venesmaa PK et al. Periprosthetic bone loss after cemented total hip arthroplasty.

Kliininen tutkimuskeskus Clinical Research Center
Julkaisutietokanta 15.4.2008 Publications Data Base 15.4.2008